GC
TVRD

Guggenheim Capital’s Tvardi Therapeutics TVRD Stock Holding History

Guggenheim Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-294
Closed -$99K – 2010
2022
Q3 		$99K Sell
294
-375
-56% -$136K ﹤0.01% 1848
2022
Q2 		$219K Buy
669
+336
+101% +$118K ﹤0.01% 1910
2022
Q1 		$145K Sell
333
-9
-3% -$3.69K ﹤0.01% 2080
2021
Q4 		$150K Buy
+342
New +$172K ﹤0.01% 2075
2017
Q4 		– Sell
-3,027
Closed -$1.49M – 2827
2017
Q3 		$1.49M Buy
+3,027
New +$1.52M ﹤0.01% 1858

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Guggenheim Capital's TVRD Position: Q4 2022 in Review

Guggenheim Capital sold out of Tvardi Therapeutics (TVRD) in Q4 2022, closing a stake of 294 shares — an estimated $99K sold.

Guggenheim Capital first reported a position in TVRD in Q3 2017 and held it in 5 quarters. The position peaked at $1.49M in Q3 2017. 160 funds tracked by Wall St. Rank hold TVRD as of Q4 2022.

  • Guggenheim Capital reported no remaining Tvardi Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Guggenheim Capital sold 294 Tvardi Therapeutics shares in Q4 2022, an estimated $99K.
  • Guggenheim Capital first reported a position in Tvardi Therapeutics in Q3 2017 and held it in 5 quarters.
  • Guggenheim Capital's Tvardi Therapeutics position peaked at $1.49M in Q3 2017.
  • 160 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2022.

Based on Guggenheim Capital's 13F filing for Q4 2022, filed 14 Feb 2023.